FLT3 and acute myeloid leukemia: Several studies 5-7, including our previous study 6, demonstrated that ATO exhibited significant anti-carcinogenic activity, promoted the degradation of the FLT3-ITD protein and inhibited its downstream signaling pathways in FLT3-ITD AML cells.